Your browser doesn't support javascript.
loading
Ebola Virus Persistence in Ocular Tissues and Fluids (EVICT) Study: Reverse Transcription-Polymerase Chain Reaction and Cataract Surgery Outcomes of Ebola Survivors in Sierra Leone.
Shantha, Jessica G; Mattia, John G; Goba, Augustine; Barnes, Kayla G; Ebrahim, Faiqa K; Kraft, Colleen S; Hayek, Brent R; Hartnett, Jessica N; Shaffer, Jeffrey G; Schieffelin, John S; Sandi, John D; Momoh, Mambu; Jalloh, Simbirie; Grant, Donald S; Dierberg, Kerry; Chang, Joyce; Mishra, Sharmistha; Chan, Adrienne K; Fowler, Rob; O'Dempsey, Tim; Kaluma, Erick; Hendricks, Taylor; Reiners, Roger; Reiners, Melanie; Gess, Lowell A; ONeill, Kwame; Kamara, Sarian; Wurie, Alie; Mansaray, Mohamed; Acharya, Nisha R; Liu, William J; Bavari, Sina; Palacios, Gustavo; Teshome, Moges; Crozier, Ian; Farmer, Paul E; Uyeki, Timothy M; Bausch, Daniel G; Garry, Robert F; Vandy, Matthew J; Yeh, Steven.
Affiliation
  • Shantha JG; Emory Eye Center, Emory University School of Medicine, Atlanta, GA, United States; University of California San Francisco, Proctor Foundation, San Francisco, CA, United States.
  • Mattia JG; Lunsar Baptist Eye Hospital, Port Loko, Sierra Leone.
  • Goba A; Kenema Government Hospital Lassa Hemorrhagic Fever Laboratory, Kenema, Sierra Leone.
  • Barnes KG; Department of Organismic and Evolutionary Biology, Harvard University, United States; Broad Institute of MIT and Harvard, Cambridge, MA, United States.
  • Ebrahim FK; World Health Organization, Geneva, Switzerland.
  • Kraft CS; Department of Pathology and Laboratory Medicine, Department of Medicine, Division of Infectious Diseases, Atlanta, GA, United States.
  • Hayek BR; Emory Eye Center, Emory University School of Medicine, Atlanta, GA, United States.
  • Hartnett JN; Tulane University School of Medicine, New Orleans, LA, United States.
  • Shaffer JG; Department of Biostatistics and Bioinformatics, Tulane School of Public Health, New Orleans, LA, United States.
  • Schieffelin JS; Tulane University School of Medicine, New Orleans, LA, United States.
  • Sandi JD; Kenema Government Hospital Lassa Hemorrhagic Fever Laboratory, Kenema, Sierra Leone.
  • Momoh M; Kenema Government Hospital Lassa Hemorrhagic Fever Laboratory, Kenema, Sierra Leone.
  • Jalloh S; Kenema Government Hospital Lassa Hemorrhagic Fever Laboratory, Kenema, Sierra Leone.
  • Grant DS; Kenema Government Hospital Lassa Hemorrhagic Fever Laboratory, Kenema, Sierra Leone; Department of Community Health, University of Sierra Leone, Freetown, Sierra Leone.
  • Dierberg K; Partners in Health, Boston, MA, United States.
  • Chang J; Partners in Health, Boston, MA, United States.
  • Mishra S; University of Toronto, Toronto, ON, Canada.
  • Chan AK; University of Toronto, Toronto, ON, Canada.
  • Fowler R; University of Toronto, Toronto, ON, Canada.
  • O'Dempsey T; University of Liverpool, Liverpool, United Kingdom.
  • Kaluma E; Comprehensive Program for Ebola Survivors, Freetown, Sierra Leone.
  • Hendricks T; Comprehensive Program for Ebola Survivors, Freetown, Sierra Leone.
  • Reiners R; Lowell and Ruth Gess Eye Hospital, Freetown, Sierra Leone.
  • Reiners M; Lowell and Ruth Gess Eye Hospital, Freetown, Sierra Leone.
  • Gess LA; Lowell and Ruth Gess Eye Hospital, Freetown, Sierra Leone.
  • ONeill K; Ministry of Health and Sanitation, Sierra Leone.
  • Kamara S; Ministry of Health and Sanitation, Sierra Leone.
  • Wurie A; Ministry of Health and Sanitation, Sierra Leone.
  • Mansaray M; Sierra Leone Association of Ebola Survivors, Freetown, Sierra Leone.
  • Acharya NR; University of California San Francisco, Proctor Foundation, San Francisco, CA, United States.
  • Liu WJ; National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
  • Bavari S; United Stated Army Medical Research Institute of Infectious Diseases, Frederick, MD, United States.
  • Palacios G; United Stated Army Medical Research Institute of Infectious Diseases, Frederick, MD, United States.
  • Teshome M; Lowell and Ruth Gess Eye Hospital, Freetown, Sierra Leone; Christian Blind Mission International, Washington, D.C., United States.
  • Crozier I; Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
  • Farmer PE; Partners in Health, Boston, MA, United States.
  • Uyeki TM; Centers for Disease Control and Prevention, Atlanta, GA, United States.
  • Bausch DG; UK Public Health Rapid Support Team Public Health England/London School of Hygiene and Tropical Medicine, London, United Kingdom.
  • Garry RF; Tulane University School of Medicine, New Orleans, LA, United States.
  • Vandy MJ; Ministry of Health and Sanitation, Sierra Leone.
  • Yeh S; Emory Eye Center, Emory University School of Medicine, Atlanta, GA, United States; Emory Global Health Institute, Emory University, Atlanta, GA, United States. Electronic address: steven.yeh@emory.edu.
EBioMedicine ; 30: 217-224, 2018 Apr.
Article in En | MEDLINE | ID: mdl-29622497
ABSTRACT

BACKGROUND:

Ebola virus disease (EVD) survivors are at risk for uveitis during convalescence. Vision loss has been observed following uveitis due to cataracts. Since Ebola virus (EBOV) may persist in the ocular fluid of EVD survivors for an unknown duration, there are questions about the safety and feasibility of vision restorative cataract surgery in EVD survivors.

METHODS:

We conducted a cross-sectional study of EVD survivors anticipating cataract surgery and patients with active uveitis to evaluate EBOV RNA persistence in ocular fluid, as well as vision outcomes post cataract surgery. Patients with aqueous humor that tested negative for EBOV RNA were eligible to proceed with manual small incision cataract surgery (MSICS).

FINDINGS:

We screened 137 EVD survivors from June 2016 - August 2017 for enrolment. We enrolled 50 EVD survivors; 46 with visually significant cataract, 1 with a subluxated lens, 2 with active uveitis and 1 with a blind painful eye due to uveitis. The median age was 24.0years (IQR 17-35) and 35 patients (70%) were female. The median logMAR visual acuity (VA) was 3.0 (Snellen VA Hand motions; Interquartile Range, IQR 1.2-3.0, Snellen VA 20/320 - Hand motions). All patients tested negative for EBOV RNA by RT-PCR in aqueous humor/vitreous fluid and conjunctiva at a median of 19months (IQR 18-20) from EVD diagnosis in Phase 1 of ocular fluid sampling and 34months (IQR 32-36) from EVD diagnosis in Phase 2 of ocular fluid sampling. Thirty-four patients underwent MSICS, with a preoperative median VA improvement from hand motions to 20/30 at three-month postoperative follow-up (P<0.001).

INTERPRETATION:

EBOV persistence by RT-PCR was not identified in ocular fluid or conjunctivae of fifty EVD survivors with ocular disease. Cataract surgery can be performed safely with vision restorative outcomes in patients who test negative for EBOV RNA in ocular fluid specimens. These findings impact the thousands of West African EVD survivors at-risk for ocular complications who may also require eye surgery during EVD convalescence.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Body Fluids / Cataract Extraction / Survivors / Hemorrhagic Fever, Ebola / Reverse Transcriptase Polymerase Chain Reaction / Ebolavirus / Eye Type of study: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adolescent / Adult / Humans Country/Region as subject: Africa Language: En Journal: EBioMedicine Year: 2018 Document type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Body Fluids / Cataract Extraction / Survivors / Hemorrhagic Fever, Ebola / Reverse Transcriptase Polymerase Chain Reaction / Ebolavirus / Eye Type of study: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adolescent / Adult / Humans Country/Region as subject: Africa Language: En Journal: EBioMedicine Year: 2018 Document type: Article Affiliation country: United States
...